Related Experiment Video
Updated: Oct 24, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
The development of multi-kinase inhibitors as pancreatic cancer therapeutics
Paul Dent1, Andrew Poklepovic2, Laurence Booth1
1Department of Biochemistry and Molecular Biology.
Abstract:
Pancreatic cancer is an almost incurable malignancy whose incidence has increased over the past 30 years. Instead of pursuing the development of modalities utilizing 'traditional' cytotoxic chemotherapeutic agents, we have explored the possibilities of developing novel multi-kinase inhibitor drug combinations to kill this tumor type. Several approaches using the multi-kinase inhibitors sorafenib, regorafenib, and neratinib have been safely translated from the bench to the bedside, with objective anti-tumor responses. This review will discuss our prior preclinical and clinical studies and discuss future clinical opportunities in this disease.
Insights
Novel multi-kinase inhibitor combinations show promise for treating pancreatic cancer, a difficult-to-cure malignancy. These targeted therapies have demonstrated safety and efficacy in early clinical trials, offering new hope for patients.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Pancreatic cancer incidence is rising, posing a significant clinical challenge due to its poor prognosis.
- Traditional chemotherapy has limited efficacy, necessitating the exploration of novel therapeutic strategies.
- Targeted therapies offer a promising alternative for managing this aggressive malignancy.
Purpose of the Study:
- To review preclinical and clinical studies on multi-kinase inhibitor combinations for pancreatic cancer.
- To explore the potential of novel drug combinations in treating this difficult-to-cure tumor type.
- To discuss future clinical opportunities for targeted therapies in pancreatic cancer management.
Main Methods:
- Investigated novel multi-kinase inhibitor drug combinations.
- Utilized sorafenib, regorafenib, and neratinib in preclinical and clinical studies.
- Assessed safety and anti-tumor responses in translated therapies.
Main Results:
- Multi-kinase inhibitor combinations were safely translated from bench to bedside.
- Objective anti-tumor responses were observed in clinical studies.
- Sorafenib, regorafenib, and neratinib demonstrated therapeutic potential.
Conclusions:
- Multi-kinase inhibitor combinations represent a viable therapeutic approach for pancreatic cancer.
- Targeted therapies offer a promising avenue for improving patient outcomes.
- Further clinical studies are warranted to optimize treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity